# PHARMACY PRE-AUTHORIZATION CRITERIA

| DRUG (S) | **Antimalarials**  
Coartem (artemether/lumefantrine)  
Mefloquine  
Chloroquine |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>POLICY #</td>
<td>13107</td>
</tr>
</tbody>
</table>
| INDICATIONS | **Coartem** tablets are indicated for treatment of acute, uncomplicated malaria infections due to *P. falciparum* in patients of 5 kg bodyweight and above.  
**Mefloquine** is indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of *Plasmodium falciparum* (both chloroquine-susceptible and -resistant strains) or by *Plasmodium vivax*.  
**Chloroquine** is indicated for the suppressive treatment and for acute attacks of malaria due to *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium ovale*, and susceptible strains of *Plasmodium falciparum*.  
Chloroquine is also indicated for the treatment of extraintestinal amebiasis. |
| CRITERIA | ConnectiCare considers **Coartem** to be medically necessary for patients who meet the following criteria:  
. For treatment of uncomplicated *Plasmodium falciparum* malaria.  
ConnectiCare considers **Mefloquine** to be medically necessary for patients who meet the following criteria:  
. For treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of *Plasmodium falciparum* (both chloroquine-susceptible and -resistant strains) or by *Plasmodium vivax*.  
ConnectiCare considers **Chloroquine** to be medically necessary for patients who meet the following criteria:  
. For treatment of acute attacks of malaria due to *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium ovale*, and susceptible strains of *Plasmodium falciparum*.  
OR  
. For the treatment of extraintestinal amebiasis |
## Pharmacy Pre-Authorization Criteria

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Antimalarials</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Coartem (artemether/lumefantrine)</td>
</tr>
<tr>
<td></td>
<td>Mefloquine</td>
</tr>
<tr>
<td></td>
<td>Chloroquine</td>
</tr>
</tbody>
</table>

### Limitations

**NOTE:**

- These medications will not be covered for patients with severe or complicated malaria.
- These medications will not be covered for the prevention of malaria. Malaria prevention is a benefit exclusion per the ConnectiCare Membership Agreement.

### References

- Facts & Comparisons Online
- Coartem full prescribing information. East Hanover, NJ. Novartis Pharmaceuticals Corp.

### P&T Review History

- 3/09, 9/09, 9/10, 12/11, 10/12, 10/13, 10/14, 11/15, 8/16, 8/17, 7/18

### Revision Record

- 8/16, 8/17